Now in its eighth year, the prize fund for this year’s Seedcorn competition run by IntertradeIreland is €280,000. Through Seedcorn, companies on the island of Ireland have already leveraged approximately €125 million worth of additional equity investment.

Commenting on the win, Jerry O’Brien, CEO said “We are delighted to have been selected to represent Munster in the upcoming Seedcorn Competition Finals. To be judged by such a distinguished panel of business experts greatly validates our business proposition as we commercially deploy our innovative diagnostic platforms and push forward to take Radisens to the next level. Private investors can avail of a unique investment opportunity by requesting a BES Information Memorandum on our website”

About Radisens Diagnostics
Radisens Diagnostics develops disruptive point-of-care diagnostic platforms and multiplexed test panels, which diagnose and monitor patients for multiple chronic and acute care conditions. This is the only point-of-care platform to integrate immunoassay, biochemistry and cellular haematology onto a single test panel. Using a finger-prick of blood, the analyser returns laboratory-grade results in the doctor’s office within minutes. Radisens Diagnostics is a convergence of medical diagnostics and consumer electronics using disruptive patent pending technology to deliver on the significant market and clinical need for decentralising diagnostics into point of care settings such as doctor’s offices, outpatient and emergency room departments, intensive care units and hospital bedsides.

Commercial Contact:
E: info @ radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909

Facilitated by CorkBIC, via their Internationalisation Programme, Radisens was chosen from hundreds of European opportunities based on numerous stringent investment criteria. Recently named 2010 European Business Angel Network of the year by EBAN, SBA creates unique financial instruments to promote innovation and growth in high potential European startups, driven by French wealth tax law.

“Radisens’ experienced multi-disciplinary team, unique business model and high growth target market were significant attractions for us to invest” said Juliana Garaizar, SBA General Manager. “There’s no doubt that point-of-care is a huge growth area and Radisens’ disruptive technology gives it a significant edge”.

“This is a significant endorsement by Europe’s premier angel network,” said Jerry O’Brien, Radisens CEO. “SBA’s track record speaks for itself. We look forward to continue working with them to build Radisens into a world leading portable diagnostics company.”

About Radisens Diagnostics

Radisens Diagnostics develops disruptive point-of-care diagnostic platforms and multiplexed test panels, which diagnose and monitor patients for multiple chronic and acute care conditions. This is the only point-of-care platform to integrate immunoassay, biochemistry and cellular haematology onto a single test panel. Using a finger-prick of blood, the analyser returns laboratory-grade results in the doctor’s office within minutes. Radisens Diagnostics is a convergence of medical diagnostics and consumer electronics using disruptive patent pending technology to deliver on the significant market and clinical need for decentralising diagnostics into point of care settings such as doctor’s offices, outpatient and emergency room departments, intensive care units and hospital bedsides.

About Sophia Business Angels Fund

Recently named European Business Angel Network of the year, Sophia Business Angels (SBA) is a select network of international serial entrepreneurs and senior managers based in the European high-tech capital of Sophia Antipolis, France. With members from 15 countries, SBA actively invests in early national, and international start-up projects which bring a significant return on investment. Given the group’s combined expertise in finance, ICT, Bio, and Energy, the SBA invests and mentor companies in ICT, CleanTech, MedTech/Health, and B2B. Over the last 6 years more than 50 SBA members have invested more than €20M of their own and managed money in more than 40 companies worldwide, with numerous successful exits.

About CorkBIC

CorkBIC is a leading interdisciplinary venture consultancy operating in the South & Mid-West of Ireland. The company has provided an integrated process for incubating and growing high potential technology companies over the last 21 years with an 85% success rate.  CorkBIC manages The Business Angel Partnership (BAP) in it’s region – a joint initiative between Enterprise Ireland, InterTrade Ireland and the Irish Business Innovation Centres (BICs). The BAP Operates on a regional basis, providing a matching service for private investors (Business Angels) and pre-screened investment opportunities in start-up, early stage and developing businesses. The BAP recently completed its 50^th investment deal resulting in investments of €18million euro into a cross section of indigenous Irish companies.

Commercial Contact:
E: info @ radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909

The nanophotonic technology has been developed as part of the Programmable Digital Camera project in the laboratory of Prof. Brian A. Wandell at Stanford led by Dr. Peter B. Catrysse. By integrating these photonic nanostructures monolithically onto a highly sensitive semiconductor detector, Radisens is miniaturising gold-standard clinical laboratory equipment into a portable platform capable of running myriad of multiplexed blood assays at point-of-care.

“Our nanophotonics research explores metal-based metamaterials and nanophotonic devices that enable efficient transport of light at the nano-scale for optical sensing applications” said Dr. Catrysse. “This is important, for example, to discriminate multiple scattering and fluorescent wavelengths inside biosensors the size of your fingernail”.

“We are pleased to access such innovative technology from Stanford,” said Jerry O’Brien, CEO of Radisens. “Nanotechnology is the key to unleashing the power of clinical laboratory diagnostics onto one portable point-of-care instrument. This allows medical practitioners to perform myriad blood tests at the patient’s side using a pin-prick of blood with results in minutes, leading to improved patient care and reduced healthcare costs.”

About Radisens Diagnostics
Radisens Diagnostics develops disruptive point-of-care diagnostic platforms and multiplexed test panels, which diagnose and monitor patients for multiple chronic and acute care conditions. This is the only point-of-care platform to integrate immunoassay, biochemistry and cellular haematology onto a single test panel. Using a finger-prick of blood, the analyser returns laboratory-grade results in the doctor’s office within minutes. Radisens Diagnostics is a convergence of medical diagnostics and consumer electronics using disruptive patent pending technology to deliver on the significant market and clinical need for decentralising diagnostics into point of care settings such as doctor’s offices, outpatient and emergency room departments, intensive care units and hospital bedsides.

Commercial Contact:
E: info @ radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909

TCD’s Institute of Molecular Medicine (IMM) and School of Medicine, in partnership with it’s nanoscience research institute, CRANN, will lead this pan-European team that has attracted funding worth approximately €12m, to develop new nanomedical technology which will enable the early and rapid diagnosis of cancer. Radisens will concentrate on developing highly sensitive portable diagnostic platforms, targeting early cancer screening in point-of-care environments such as GP clinics, community centres and outpatient departments.

Professor Dermot Kelleher, Head of TCD School of Medicine and IMM Director said:  “This is a huge vote of confidence and recognises Irish leadership in the cutting edge field of nanomedicine.  This research programme will address some of the most important questions in human medicine relating to diagnosis and treatment of cancer, using 21st century experience and know-how in nanotechnology, and we are looking forward to the time when patients will benefit from these innovative technologies.”

“This is a huge endorsement in the innovative platform technology we are developing at Radisens” said Jerry O’Brien, CEO of Radisens. “Developing a portable handheld instrument to screen for various cancers using a pin-prick of blood will add significantly to early cancer diagnosis and increased survival rates”.

About Radisens Diagnostics
Radisens Diagnostics develops disruptive point-of-care diagnostic platforms and multiplexed test panels, which diagnose and monitor patients for multiple chronic and acute care conditions. This is the only point-of-care platform to integrate immunoassay, biochemistry and cellular haematology onto a single test panel. Using a finger-prick of blood, the analyser returns laboratory-grade results in the doctor’s office within minutes. Radisens Diagnostics is a convergence of medical diagnostics and consumer electronics using disruptive patent pending technology to deliver on the significant market and clinical need for decentralising diagnostics into point of care settings such as doctor’s offices, outpatient and emergency room departments, intensive care units and hospital bedsides.

About the Cancer Research Programme
TCD School of Medicine and CRANN Principal Investigator, Professor Yuri Volkov, will lead a European team of researchers to create advanced medical diagnostic devices, enabled by nanotechnology, which will allow the early and rapid diagnosis of cancer.   Importantly the new technology when developed will also enable the early detection of specific cancer types, leading to improved patient care. The programme will be led by a team of clinical medical researchers from St James Hospital Campus, in collaboration with the nanoscience Institute CRANN at TCD.

Commercial Contact:
E: info @ radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909

Kevin joined Alta Berkeley VC in 2003 and has a 20-year track-record of building and managing technology  companies in both Europe and the US. Prior to joining Alta Berkeley, Kevin held the position of President and CEO of ParthusCeva. He also led several successful high-technology start-up activities, including Parthus Technologies which had a successful IPO on the LSE and NASDAQ in 2000, and the StrongARM microprocessor business, acquired by Intel in 1998. Prior to returning to Europe in 1998, Kevin spent 10 years working on several high-tech businesses. He was the General Manager of the StrongARM business in Palo Alto, CA prior to its acquisition by Intel in 1998, and also worked on the original Alpha microprocessor for Digital Equipment Corporation. Before moving to the United States, Kevin worked on high-speed processor design for Philips BV in Eindhoven and in Dublin. He also spent four years working in the research labs at the NMRC (National Microelectronics Research Centre) attached to University College, Cork, Ireland.

Gary was Group Director, Finance & Enterprise Technology, at Allied Irish Banks (AIB) from May 1997 to December 2005, was a member of the main Board of AIB and was also on the Board of M&T, AIB’s associate in the United States. Prior to that, Gary was Group Vice President at Nortel Networks Europe after starting his management career at Deloitte & Touche. He served on the Board of the Industrial Development Authority (IDA) of Ireland for 10 years until he retired in December 2005. Gary was appointed a Director of Elan plc in May 2005, and is also a Director of Greencore Group. He is Chairman of a number of private companies. Gary is a chartered accountant.

“We are delighted to welcome both Kevin and Gary on board, leveraging their proven track records of positioning startups for high growth, attracting the necessary funding and implementing strong corporate governance”  commented Jerry O’Brien, Radisens CEO. “Having such high calibre members on our Board is a testament to our progress towards handheld haematology analysers”

About Radisens Diagnostics
Radisens Diagnostics develops disruptive point-of-care diagnostic platforms and multiplexed test panels, which diagnose and monitor patients for multiple chronic and acute care conditions. This is the only point-of-care platform to integrate immunoassay, biochemistry and cellular haematology onto a single test panel. Using a finger-prick of blood, the analyser returns laboratory-grade results in the doctor’s office within minutes. Radisens Diagnostics is a convergence of medical diagnostics and consumer electronics using disruptive patent pending technology to deliver on the significant market and clinical need for decentralising diagnostics into point of care settings such as doctor’s offices, outpatient and emergency room departments, intensive care units and hospital bedsides.

Commercial Contact:
E: info @ radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909

About Radisens Diagnostics
Radisens Diagnostics develops disruptive point-of-care diagnostic platforms and multiplexed test panels, which diagnose and monitor patients for multiple chronic and acute care conditions. This is the only point-of-care platform to integrate immunoassay, biochemistry and cellular haematology onto a single test panel. Using a finger-prick of blood, the analyser returns laboratory-grade results in the doctor’s office within minutes. Radisens Diagnostics is a convergence of medical diagnostics and consumer electronics using disruptive patent pending technology to deliver on the significant market and clinical need for decentralising diagnostics into point of care settings such as doctor’s offices, outpatient and emergency room departments, intensive care units and hospital bedsides.

About Global Growth Network
The Global Growth Network (GGN) was established to help small to mid-sized firms grow their business overseas by providing experienced international expertise. The GGN helps the building of overseas businesses by researching the market, writing a business plan, establishing a supply chain, recruiting staff, developing a sales network, or building a factory. The tools utilized would be a keen ear for the voice of internal and external customers, an analytic approach tempered by cross-cultural sensitivity, and an international network of relationships built over twenty years.

About Cicom
Cicom is a private company that combines French, European and world leaders in the sectors of facilities management and state of the art information technology. Founded in 1995 to manage and run the Advanced International Communication Centre (CICA) in Sophia Antipolis. Cicom was named a member of the European Business and Innovation Centre Network in 1998, has managed the European Telecom Innovation Center since 2001, and became a member of the European Space Incubator Network in 2002. Cicom successfully incubates numerous ITC and Telecoms SMEs from France and abroad, consults on the development of Technoparks and is involved in numerous European projects supporting the enhancement and innovation of SMEs in Europe.

About CorkBIC
CorkBIC is a leading interdisciplinary venture consultancy in the South West of Ireland. The company provides an integrated process for incubating and growing high potential technology driven companies. CorkBIC identifies, selects and develops about 12 higher potential startups per year and works as a hands-on catalyst or project developer in infrastructure gap initiatives.

About Sophia Business Angels
The Sophia Business Angels is a select group of international serial entrepreneurs and senior managers coming together once a month in the European high-tech capital of Sophia Antipolis, France. Today, the group numbers 50 + strong, hails from 15 countries stretching from South America to North America to the Middle East and to Europe, and has a proven serious interest to invest early in local, national, and international start-up projects which bring a significant return on investment. Given the group’s combined expertise in finance, ICT, Bio, and Energy, the SBA Members have been able to work as a club to find, fashion, and fund investments for their members throughout the world.

About EBAN
EBAN serves business angels, business angel networks, seed funds and other early stage investment professionals across Europe. EBAN is the representative in Brussels through direct and indirect membership of more than 250 business angel networks in Europe. These in turn federate some 20.000 angels, and receive about 40.000 business plans a year. EBAN brings together over 100 member organisations in 27 countries today.

About Succès Europe
Succès Europe is a Sophia Antipolis based European investment holding focusing on early-stage investments in the CleanTech, MedTech, ICT and B2B sectors. The founding shareholders and Investment Committee are all serial entrepreneurs or international managers and have founded or been heavily associated with such success stories as SES, GemPlus, Kaerys, COMEX, Adobe, MicroSoft, Nokia, LavaLife, etc. Succès Europe has an active investment philosophy which foresees using the experience, expertise, and network of their founding shareholders and Investment Committee to help their investee companies to global success.

Commercial Contact:
E: info @ radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909

» Full story

About Radisens Diagnostics

Radisens Diagnostics develops disruptive point-of-care diagnostic platforms and multiplexed test panels, which diagnose and monitor patients for multiple chronic and acute care conditions. This is the only point-of-care platform to integrate immunoassay, biochemistry and cellular haematology onto a single test panel. Using a finger-prick of blood, the analyser returns laboratory-grade results in the doctor’s office within minutes. Radisens Diagnostics is a convergence of medical diagnostics and consumer electronics using disruptive patent pending technology to deliver on the significant market and clinical need for decentralising diagnostics into point of care settings such as doctor’s offices, outpatient and emergency room departments, intensive care units and hospital bedsides.

Commercial Contact:
E: info @ radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909